Key facts
- Notable investors include Lapam Capital, Senmiao Biotechnology.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Ruizhen Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Ruizhen Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ruizhen Pharmaceutical
Operator of a pharmaceutical company intended for the treatment of liver tumors. The company focuses on targeted drug research, advanced delivery systems and clinical innovation through a specialized R&D team and modern biotechnology infrastructure, enabling the healthcare sector to access more precise, effective, and scientifically advanced approaches to liver tumor treatment and patient care.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2019
- Ownership
- Privately Held (backing)
Ruizhen Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ruizhen Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ruizhen Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.